Drug Status: Marketed Drug
CRESTOR is a member of the statin class; for the treatment of dyslipidaemia. CRESTOR reduces LDL-C (‘bad’ cholesterol) and raises HDL-C (‘good’ cholesterol).CRESTOR was initially developed by the Japanese pharmaceutical company Shionogi and in-licensed to AstraZeneca in April 1998.For rosuvastatin clinical information please visit www.rosuvastatininformation.com
For further information on Crestor and links to other product specific and disease area websites please click here.
Please consult the prescribing information for the country concerned on the approved use of drug.
- collapse Efficiency of rosuvastatin versus the fixed combination of Ezetimibe/Simbastatin to reduce the cholesterol levels in outpatients in a realistic enviroment. A Retrospective Study
- collapse Prevalence of Atherosclerotic Disease in Asian Subjects Not on Lipid-lowering Agents, But With at Least Two CVD Risk Factors
- collapse Statins and risk of myocardial infarction in real life in France
- collapse Open-Labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)
- collapse InPractice Survey on the treatment of hypercholesterolemia
- collapse Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
- collapse Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug eluting stent (DES) implantation who take statins
- collapse Evaluation of compliance with management of Acute Coronary Syndrome on discharge from Cardiac Intensive Care unit. This is a national, multicentre, longitudinal, prospective, cohort follow-up, observational study.
- collapse Interventions study for the control of diabetes mellitus type 2 in obese women
- collapse A non-interventional study evaluating Quality Of Life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. A 9-month, observational, multicentric prospective study.
